Watch More Highlights
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses findings from a long-term follow-up of the combination of eprenetapopt and azacitidine in patients with TP53-mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). This is especially important information for advanced practitioners, given the fact that these gene mutations are found in up to 20% of patients with MDS or AML and 30% to 40% of treatment-related MDS/AML cases, representing a distinct molecular cohort with poor outcomes (Abstract 246).